Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
DNAJB1-PRKACA, Active (P51-19BG)

DNAJB1-PRKACA, Active (P51-19BG)

  • $259.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human fusion protein DNAJB1(2-70)-PRKACA (16-351) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :DNAJB1(2-70)-PRKACA (16-351)

Genbank Number :
NM_006145
NM_002730

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay

Molecular Weight :~70 kDa

Gene Aliases :
DNAJB1: Hsp40, DNAJ1
PRKACA: PKACA, PPNAD4

References :
1. Honeyman, J N. et al: Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343: 1010-1014, 2014.

2. Kastenhuber, E R. et al: DNAJB1–PRKACA fusion kinase interacts with β- and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. PNAS 14(50): 13076-13084, 2017.

Scientific Background :DNAJB1-PRKACA is a chimeric fusion between the catalytic subunit alpha (PRKACA) of protein kinase A and the J-domain of the heat shock protein 40 (DNAJB1). A single segmental genetic deletion in one copy of chromosome 19 combines the first exon of DNAJB1 with exon 2 through 10 of PRKACA and results in the chimeric gene DNAJB1-PRKACA (1). Fusion kinase, DNAJB1-PRKACA is implicated in development of Fibrolamellar Hepatocellular Carcinoma (FL-HCC), thus is a potential oncogenic factor and a candidate drug target for FL-HCC (2).

Product Sheets (By Lot #) :

 I3037-9.pdf

Research Areas :Cancer,Cardiovascular Disease